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Objective: To evaluate myeloid differentiation primary response gene 88 (MyD88) and Toll-like receptor
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308Patients and Methods: We conducted centralized immunohistochemical staining, semi-
quantitative scoring, and survival analysis in 5263 patients participating in the Ovarian Tumor
Tissue Analysis consortium. Patients were diagnosed between January 1, 1978, and December
31, 2014, including 2865 high-grade serous ovarian carcinomas (HGSOCs), with more than
12,000 person-years of follow-up time. Tissue microarrays were stained for MyD88 and TLR4,
and staining intensity was classiﬁed using a 2-tiered system for each marker (weak vs strong).
Results: Expression of MyD88 and TLR4 was similar in all histotypes except clear cell ovarian
cancer, which showed reduced expression compared with other histotypes (P<.001 for both). In
HGSOC, strong MyD88 expression was modestly associated with shortened overall survival
(hazard ratio [HR], 1.13; 95% CI, 1.01-1.26; P¼.04) but was also associated with advanced stage
(P<.001). The expression of TLR4 was not associated with survival. In low-grade serous ovarian
cancer (LGSOC), strong expression of both MyD88 and TLR4 was associated with favorable
survival (HR [95% CI], 0.49 [0.29-0.84] and 0.44 [0.21-0.89], respectively; P¼.009 and P¼.02,
respectively).
Conclusion: Results are consistent with an association between strong MyD88 staining and
advanced stage and poorer survival in HGSOC and demonstrate correlation between strong
MyD88 and TLR4 staining and improved survival in LGSOC, highlighting the biological dif-
ferences between the 2 serous histotypes.
ª 2017 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. This is an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/) n Mayo Clin Proc. 2018;93(3):307-320E pithelial ovarian cancer (EOC) remainsthe ﬁfth leading cause of cancer deathamong women in United States, result-
ing in more than 14,000 estimated deaths in
2017.1 Less than 40% of patients with EOC
are cured, because more than 70% of patients
are diagnosed with advanced disease (stage III
or IV).2 The frustrating truth is that since
platinum-based treatment was introduced
more than 30 years ago, the overall survival
rate of women with EOC has changed little3;
most patients will relapse and die from their
disease despite response to ﬁrst-line surgery
and chemotherapy.4 Thus, novel therapeutic
approaches for EOC are needed.5
The innate immune system recognizes the
presence of bacterial pathogens through the
expression of a family of membrane receptors
known as Toll-like receptors (TLRs).6
Although their expression is well established
in immune cells, TLRs are also found in a
myriad of human cancers, including EOC.7
Among all the TLRs, Toll-like receptor 4
(TLR4) is perhaps the most extensively inves-
tigated.8 Cumulating studies have suggested
that coexpression of TLR4, along with myeloid
differentiation primary response gene 88
(MyD88), a TLR signaling adapter protein,
associates with poor prognosis in EOC by
facilitating proliferation, survival, and chemo-
resistance of EOC cells through the activation
of various proinﬂammatory cytokines andMayo Clin Proc. n March 201antiapoptotic proteins.9-11 An additional
report of atractylenolide-I, a novel TLR4-
antagonizing agent, has been shown to sensi-
tize EOC cells to paclitaxel by blocking the
MyD88/TLR4 pathway.12
We previously analyzed immunohisto-
chemical staining of MyD88 and TLR4 in a
collection of approximately 450 EOC cases
seen at Mayo Clinic; we found that the expres-
sion of both MyD88 and TLR4 was associated
with poorer overall survival at P< .05.13
Although adjustment of clinical covariates
such as age, stage, histology, grade, and surgi-
cal debulking status attenuated these results,
MyD88- and TLR4-associated risk estimates
remained suggestive and indicated the need
for larger analyses.13
Therefore, we here report analysis of an in-
dependent EOC study population of more
than 10 times the previous sample size, allow-
ing for a more detailed assessment of prog-
nosis by histotype with consideration of
combined expression and clinical subsets.
PATIENTS AND METHODS
Eligible cases with primary diagnosis of epithe-
lial ovarian, peritoneal, or fallopian tube cancer
were diagnosed between January 1, 1978, and
December 31, 2014, and enrolled into 21
collaborative studies participating in the
Ovarian Tumor Tissue Analysis consortium.14-17
Mayo Clinic cases in the original report were8;93(3):307-320 n https://doi.org/10.1016/j.mayocp.2017.10.023
www.mayoclinicproceedings.org
FIGURE 1. Representative immunohistochemical stains for MyD88 and
TLR4 expression. A, High-grade serous carcinoma with weak MyD88
staining. B, High-grade serous carcinoma with weak TLR4 staining. C, High-
grade serous carcinoma with strong MyD88 staining. D, High-grade serous
carcinoma with strong TLR4 staining. MyD88 ¼ myeloid differentiation
primary response gene 88; TLR4 ¼ Toll-like receptor 4.
MYD88 AND TLR4 IN EPITHELIAL OVARIAN CANCERnot included.13 Histopathological classiﬁca-
tion for each case was provided by each
contributing study, which was supplemented
by additional pathologic review guided by
WT1 and p53 IHC staining for most studies
as described previously.14 From among 7377
cases arrayed on tissue microarrays (TMAs),
we excluded those found to be duplicated
across studies (n¼4), missing vital status at
last follow-up (n¼288), missing time to last
follow-up (n¼17), missing age at diagnosis
(n¼11), found to be nonepithelial (n¼63),
missing tumor behavior (n¼2), or unable to
be scored for both markers because of inade-
quate amount of arrayed tumor tissue
(n¼1729) (Supplemental Figure, available
online at http://www.mayoclinicproceedings.
org). Thus, up to 5263 cases were used for
analysis, including 4694 with tumors of the
5 major invasive histotypes (high-grade serous
ovarian carcinoma [HGSOC]; endometrioid
ovarian carcinoma [ENOC]; clear cell ovarian
carcinoma [CCOC]; mucinous ovarian carci-
noma [MOC]; and low-grade serous ovarian
carcinoma [LGSOC]). As described below,
additional cases were excluded for one marker
or the other. Supplemental Table 1 (available
online at http://www.mayoclinicproceedings.
org) presents characteristics of participating
studies, including sample size, location, and
data collection methods, and Supplemental
Table 2 (available online at http://www.
mayoclinicproceedings.org) presents clinical
characteristics of analyzed cases.
Immunohistochemistry
Sections of TMAs were provided for centralized
immunostaining at the Mayo Clinic, Rochester,
Minnesota. For MyD88, the primary antibody
was the rabbit polyclonal antibody NBP1-
19785 (Novus Biologicals)18 and the detection
system was Polymer Reﬁne Detection System
(Leica). This system included the hydrogen
peroxidase block, postprimary and polymer re-
agent 3,30-diaminobenzidine (DAB), and hema-
toxylin. Immunostaining visualization was
achieved by incubating slides for 10 minutes
in DAB and DAB buffer (1:19 mixture) from
the Bond Polymer Reﬁne Detection System.
To this point, slides were rinsed between steps
with 10 BondWash Buffer (Leica). Before and af-
ter DAB incubation, slides were rinsed in
distilled water. For TLR4, the monoclonalMayo Clin Proc. n March 2018;93(3):307-320 n https://doi.org/10.1
www.mayoclinicproceedings.organtibody 3B6 (Novus Biologicals) was used as
the primary detection antibody.19 The detec-
tion system was the Envision Flex System
(Dako); the reagents were the Flex Peroxidase-
Blocking for 5 minutes, Flex/HRP for 20
minutes, and Flex DABþ Chromogen/Sub-
strate Buffer (1 drop of DAB per 1 mL of sub-
strate buffer) for 5 minutes. Slides were
counterstained for 5minutes using Schmidt he-
matoxylin and molecular biology grade water
(1:1 mixture), followed by several rinses in 10
Bond wash buffer and distilled water; this is
not the hematoxylin provided with the Reﬁne
kit. Once the immunochemistry processes
were completed, slides were removed from
the stainer and rinsed in tap water for 5 mi-
nutes. Slides were dehydrated in increasing
concentrations of ethyl alcohol and cleared in
3 changes of xylene before permanent cover-
slipping in xylene-based medium.Scoring
Figure 1 shows representative stains with each
score for MyD88 and TLR4. For MyD88, mul-
tiple cores from a subset of 312 cases were eval-
uated blindly by 2 independent pathologists
(M.K. and P.R.) using a 4-tiered system016/j.mayocp.2017.10.023 309
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310(negative, weak, moderate, and strong), and a
weighted kappa statistic was estimated. Then,
differences in interpretation were discussed at
a multiheaded microscope. Assessments of
concordance in scores across these MyD88
cores indicated only modest levels of agreement
(weighted k, 0.55; 95% CI, 0.48-0.62); dichot-
omization of MyD88 expression into negative/
weak and moderate/strong substantially
increased agreement (k, 0.81; 95% CI, 0.72-
0.90). Because of this, all subsequent analyses
of MyD88 and TLR4 expression used a dichot-
omous classiﬁcation, henceforth referred to as
weak (negative or weak expression) or strong
(moderate or strong expression).
The cohort was subsequently split, with
51% of cases scored for MyD88 by M.K. and
49%by P.R. The TLR4was evaluated by a single
pathologist (M.K.). For cases with more than 1
scored core, the highest score was used in anal-
ysis. Because TMA cores with less than 25%
epithelial tumor component were considered
uninterpretable, a total of 137 cases were not
scored for MyD88 (therefore, 5126 analyzed)
and 676 cases were not scored for TLR4 (there-
fore, 4587 analyzed) (Supplemental Figure).
Analysis
Three sets of potential prognostic factors were
evaluated: tumor expression of MyD88, of
TLR4, and combinations of these 2. All
statistical tests were 2-sided and uncorrected for
multiple testing; all analyses were carried out us-
ing the SAS (SAS System, Inc) and R software (R
Foundation for Statistical Computing) systems.
Details on statistical analysis are provided in
Supplemental Methods (available online at
http://www.mayoclinicproceedings.org).
RESULTS
Clinical Characteristics of Study Cohort
The mean age at diagnosis for study partici-
pants was 58.0 years (Supplemental Table 2).
Most of the cancers were advanced stage and
high grade, and more than half of the patients
were deceased as of last follow-up. Among the
5 main invasive EOC histotypes (N¼4694),
HGSOC was the most common (N¼2865,
61%), followed by ENOC (N¼670, 14%),
CCOC (N¼616, 13%), MOC (N¼355, 7%),
and LGSOC (N¼188, 4%). Ten-year overall
Kaplan-Meier survival estimates were 19%Mayo Clin Proc. n March 201for HGSOC, 66% for ENOC, 50% for
CCOC, 53% for MOC, and 30% for LGSOC.
Intracellular Distribution of Staining
The MyD88 staining distribution was mostly
cytoplasmic with some membranous staining,
consistent with the primarily cytoplasmic
localization of the MyD88 adapter protein.
Toll-like receptor 4 staining was distributed
to both the cytoplasm and the plasma mem-
brane. Toll-like receptor 4 is typically
expressed both on the plasma membrane
and in endosomes of myeloid leukocytes;
localization of TLR4 expression on tumor cells
has not previously been reported.
Distribution of Expression by Histotype
Distributions of MyD88 and TLR4 expression
among the 5 most common invasive histotypes
are presented in Table 1. In general, strong
expression was more common than weak
expression, with a notable exception: a minority
of CCOCs (40%) showed strong TLR4 expres-
sion. Expression distributions for each marker
were similar across HGSOCs, ENOCs, MOCs,
and LGSOCs (68%-74% strong for MyD88;
71%-74% strong for TLR4). However, the
expression in CCOCs was lower (only 59%
strong for MyD88; only 40% strong for TLR4)
compared with that of these histotypes com-
bined (MyD88P<.001; TLR,P<.001). Distribu-
tions among additional histopathological groups
are provided in Supplemental Table 3 (available
online at http://www.mayoclinicproceedings.
org). Both MyD88 and TLR4 tended to be coex-
pressed, such that 67% of subjects either had
low expression of both or high expression of
both (c2 tests for independence P<.001, both
overall and subset to the 5 most common inva-
sive histotypes).
Clinical Correlates Among Women With
HGSOC
Among women with HGSOC, associations of
expression with clinical features are presented
in Supplemental Table 4 (available online at
http://www.mayoclinicproceedings.org). Expres-
sion was similar regardless of age at diagnosis
(P¼.65 for MyD88 and P¼.12 for TLR4).
High-grade serous ovarian carcinomas with
strong MyD88 expression were more likely
to be advanced stage than those with weak
MyD88 expression (82% vs 75%, P<.001).8;93(3):307-320 n https://doi.org/10.1016/j.mayocp.2017.10.023
www.mayoclinicproceedings.org
TABLE 1. Associations of MyD88 and TLR4 Expression With Overall Survival Among Cases With the 5 Most Common Invasive Epithelial
Ovarian Cancer Histotypesa,b
Histotype Level
MyD88 TLR4
Subjects, n (%) No. of events HR (95% CI) P Subjects, n (%) No. of events HR (95% CI) P
High-grade serous Weak 712 (26) 450 Reference .04 734 (29) 490 Reference .35
Strong 2064 (74) 1426 1.13 (1.01-1.26) 1788 (71) 1247 1.06 (0.94-1.18)
Endometrioid Weak 213 (32) 58 Reference .82 169 (28) 48 Reference .99
Strong 447 (68) 109 0.96 (0.69-1.34) 443 (72) 105 1.00 (0.67-1.49)
Clear cell Weak 250 (41) 100 Reference .96 335 (60) 142 Reference .76
Strong 358 (59) 158 1.01 (0.77-1.32) 226 (40) 93 1.04 (0.79-1.38)
Mucinous Weak 96 (28) 36 Reference .64 79 (26) 40 Reference .11
Strong 249 (72) 96 1.12 (0.70-1.79) 224 (74) 71 1.54 (0.91-2.60)
Low-grade serous Weak 49 (27) 26 Reference .009 42 (29) 21 Reference .02
Strong 133 (73) 64 0.49 (0.29-0.84) 103 (71) 54 0.44 (0.21-0.89)
aHR ¼ hazard ratio; MyD88 ¼ myeloid differentiation primary response gene 88; TLR4 ¼ Toll-like receptor 4.
bAdjusted for study, age (continuous), and stage (I/II, III/IV, unknown).
MYD88 AND TLR4 IN EPITHELIAL OVARIAN CANCERThe expression of TLR4 did not differ by tu-
mor stage (P¼.75). Expression did not differ
by extent of residual disease or known breast
cancer susceptibility gene 1 (BRCA1) or breast
cancer susceptibility gene 2 (BRCA2) patho-
genic mutation.
Associations of Expression With Overall
Survival by Histotype
Women with HGSOC and strong MyD88
expression had slightly poorer survival than
did those with weak expression (unadjusted
log-rank test P<.001; Figure 2). Results atten-
uated somewhat in age- and stage-adjusted
Cox regression analyses but remained statisti-
cally signiﬁcant (hazard ratio [HR], 1.13;
95% CI, 1.01-1.26; P¼.04; Table 1). We
found no evidence of a survival association
with MyD88 expression for women with
ENOC, CCOC, and MOC. Women with
LGSOC and strong MyD88 expression had
marginally better survival outcomes than did
those with weak MyD88 expression (unad-
justed log-rank test P¼.14, Figure 2). This
association strengthened after adjustment for
study, age, and stage (Cox regression HR,
0.49; 95% CI, 0.29-0.84; P¼.009; Table 1).
Sensitivity analyses adjusting only for age
and tumor stage demonstrated a similar pro-
tective effect of high MyD88 levels on survival
(HR, 0.61; 95% CI, 0.39-0.97; P¼.04).
For TLR4, even with nearly 12,000 years
of follow-up for 2522 HGSOC cases (1737
deaths), we found no discernable evidence
that survival differed by TLR4 expression.Mayo Clin Proc. n March 2018;93(3):307-320 n https://doi.org/10.1
www.mayoclinicproceedings.orgKaplan-Meier curves overlapped considerably
(Figure 3), and Cox regression analyses adjust-
ing for age, stage, and study site were not
statistically signiﬁcant (HR, 1.06; 95% CI,
0.94-1.18; Table 1). There was some evidence
for nonproportional hazards over time for
women with HGSOC (P¼.01). This can be
seen in Figure 3, where the Kaplan-Meier
curves cross in such a way that strong expres-
sion has a slight protective effect within the
ﬁrst 5 years of follow-up, then a slightly
increased prognostic effect in years 5 through
10. However, in no instance is the difference
between the 2 curves clinically meaningful.
Moreover, time-stratiﬁed Cox regression anal-
ysis found no evidence of association with sur-
vival in either the ﬁrst 5 years (P¼.37) or the
last 5 years of follow-up (P¼.80).
We also did not observe any signiﬁcant
associations between TLR4 expression and
overall survival for women with ENOC (Cox
regression P¼.99) or CCOC (P¼.76)
(Table 1). In univariate analyses, MOC tu-
mors with strong TLR4 expression tended to
fare better than those with weak expression
(log-rank test P<.001; Figure 3). This associ-
ation reversed direction in Cox regression an-
alyses adjusting for study, age, and stage,
such that MOC tumors with strong TLR4
expression fared more poorly than did those
with weak expression, although the results
failed to reach statistical signiﬁcance (HR,
1.54; 95% CI, 0.91-2.60; P¼.11; Table 1).
Sensitivity analyses revealed that adjustment
for study site had the most impact on this016/j.mayocp.2017.10.023 311
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FIGURE 2. Kaplan-Meier overall survival plots by MyD88 expression for the 5 most common invasive ovarian cancer histotypes. A,
High-grade serous ovarian cancer (N¼2776); B, endometrioid ovarian cancer (N¼660); C, clear cell ovarian cancer (N¼608); D,
mucinous ovarian cancer (N¼345); and E, low-grade serous ovarian cancer (N¼182). MyD88 ¼ myeloid differentiation primary
response gene 88.
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312change in direction of association: analyses
adjusting for age and tumor stage only were
essentially null (HR, 1.01; 95% CI, 0.67-
1.54; P¼.95). Kaplan-Meier curves displayed
some evidence of a survival advantage for
patients with LGSOC with strong TLR4
expression compared to those with weak
expression. This effect was even more pro-
nounced and reached statistical signiﬁcance
in adjusted Cox regression analyses (HR for
strong expression compared with weak,
0.44; 95% CI, 0.21-0.89; P¼.02; Table 1).
As with MOC, analyses adjusting only for
age and tumor stage were less striking (HR,
0.72; 95% CI, 0.43-1.20; P¼.21).
Associations of Combined Expression With
Overall Survival by Histotype
Because MyD88 and TLR4 coexpression has
been shown to affect in vitro function,9-11Mayo Clin Proc. n March 201we examined associations between survival
and combination of expression (Figure 4
and Table 2). For women with HGSOC,
those with strong MyD88 expression had
poorer survival than those with weak
MyD88 expression, regardless of TLR4
expression. As with the uncombined analyses
in Table 1, we found no discernable patterns
with survival and combinations of MyD88
and TLR4 expression in women with
ENOC or CCOC (Cox regression P>.50 for
each). Consistent with the associations
observed in uncombined analyses, we saw lit-
tle or no separation of survival curves for
MyD88 expression, regardless of TLR4
expression, and we saw some association be-
tween high TLR4 expression and survival
regardless of MyD88 expression for MOC tu-
mors (P¼.01; Figure 4). Again, consistent
with uncombined analyses, associations8;93(3):307-320 n https://doi.org/10.1016/j.mayocp.2017.10.023
www.mayoclinicproceedings.org
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FIGURE 3. Kaplan-Meier overall survival plots by TLR4 expression for the 5 most common invasive ovarian cancer histotypes. A,
High-grade serous ovarian cancer (N¼2522); B, endometrioid ovarian cancer (N¼612); C, clear cell ovarian cancer (N¼561); D,
mucinous ovarian cancer (N¼303); and E, low-grade serous ovarian cancer (N¼145). TLR4 ¼ Toll-like receptor 4.
MYD88 AND TLR4 IN EPITHELIAL OVARIAN CANCERattenuated to nonsigniﬁcance after multivar-
iate adjustment (Cox regression P¼.52,
Table 2). Compared with LGSOC tumors
with weak expression of both markers, those
with weak MyD88 and strong TLR4 expres-
sion (HR, 0.87; 95% CI, 0.28-2.71) and
those with strong MyD88 and weak TLR4
expression (HR, 0.78; 95% CI, 0.28-2.21)
had slightly longer survival. The LGSOC tu-
mors with strong expression for both
MyD88 and TLR4 had the longest survival
times of the 4 expression groups (HR, 0.33;
95% CI, 0.13-0.85). We found no statisti-
cally signiﬁcant survival interactions between
MyD88 expression and TLR4 expression,
either overall or by any of the histotypes in
Table 1, indicating that effects of MyD88
expression on survival are not modiﬁed by
expression of TLR4 and vice versa (interac-
tion P>.05 for each).Mayo Clin Proc. n March 2018;93(3):307-320 n https://doi.org/10.1
www.mayoclinicproceedings.orgAssociations of Expression With Overall
Survival in HGSOC Subsets
We evaluated the association between MyD88
and TLR4 expression and overall survival of
HGSOCs by the extent of disease following sur-
gery, BRCA1 or BRCA2 pathogenic mutation,
and treatment (Table 3). For MyD88, the
modest prognostic association remained; HRs
were elevated in each group. For TLR4, there
was a suggestion of effect modiﬁcation by extent
of residual disease (macroscopic disease: HR,
1.17; 95% CI, 0.98-1.39; P¼.084; no macro-
scopic disease: HR, 0.76; 95% CI, 0.59-0.97;
P¼.03), but tests for interaction failed to reach
statistical signiﬁcance (P¼.13). We also
observed a potential prognostic association of
TLR4 in BRCA1 mutation carriers (HR, 2.69;
95% CI, 1.25-5.81; P¼.01) and a potential pro-
tective effect in BRCA2 carriers (HR, 0.26; 95%
CI, 0.08-0.84; P¼.02), but tests for interaction016/j.mayocp.2017.10.023 313
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FIGURE 4. Kaplan-Meier overall survival plots by MyD88 and TLR4 expression for the 5 most common invasive ovarian cancer
histotypes. A, High-grade serous ovarian cancer (N¼2433); B, endometrioid ovarian cancer (N¼602); C, clear cell ovarian cancer
(N¼293); D, mucinous ovarian cancer (N¼553); and E, low-grade serous ovarian cancer (N¼139). MyD88 ¼ myeloid differentiation
primary response gene 88; TLR4 ¼ Toll-like receptor 4.
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314again failed to reach statistical signiﬁcance
(P¼.08), perhaps due in part to small cell sizes
within the mutation-positive groups.
Combining MyD88 and TLR4 expression did
not reveal additional patterns or interactions be-
tween the 2 expression values (Supplemental
Table 5, available online at http://www.
mayoclinicproceedings.org).
Additional Analyses
Because some previous ovarian cancer studies
have combined LGSOC and HGSOC, we also
analyzed invasive serous cases as a group,
including those with missing grade. As ex-
pected, we found that combining the 2 groups
together nulliﬁed the modestly higher
expression-related associations observed in
HGSOCs and the strikingly lower risks obser-
ved in LGSOCs (P¼.21 for MyD88 and P¼.49Mayo Clin Proc. n March 201for TLR4; see Supplemental Table 6, available
online at http://www.mayoclinicproceedings.
org). Combining LGSOCs with 127 serous
borderline tumors (a potential precursor lesion)
resulted in a similar protective association with
strong MyD88 and TLR4 expression levels that
we had observed in LGSOC-only analyses. No
discernable patterns were observed between
expression (including combined) and survival
(including interactions) in other histological
groups (Supplemental Tables 6 and 7, available
online at http://www.mayoclinicproceedings.org),
although results for many of these should be
interpreted with caution because of low sample
sizes.
Last, among the 5 major histotypes, time
to disease progression was known for approx-
imately half the cases. Progression-free survival
results were similar to overall survival results8;93(3):307-320 n https://doi.org/10.1016/j.mayocp.2017.10.023
www.mayoclinicproceedings.org
TABLE 2. Associations of Combinations of MyD88 and TLR4 Expression With Overall Survival Among Cases With the 5 Most Common
Invasive Epithelial Ovarian Cancer Histotypesa,b
Histotype MyD88 TLR4 Subjects, n No. of events HR (95% CI) P
High-grade serous Weak Weak 246 149 Reference .10
Strong 323 217 1.15 (0.92-1.42)
Strong Weak 450 312 1.23 (1.01-1.51)
Strong 1414 991 1.25 (1.04-1.50)
Endometrioid Weak Weak 85 22 Reference .72
Strong 103 27 1.18 (0.65-2.13)
Strong Weak 75 23 1.40 (0.75-2.63)
Strong 339 78 1.08 (0.65-1.79)
Clear cell Weak Weak 162 64 Reference .82
Strong 61 21 1.18 (0.70-1.99)
Strong Weak 168 77 1.18 (0.82-1.69)
Strong 162 70 1.10 (0.76-1.60)
Mucinous Weak Weak 28 14 Reference .52
Strong 43 13 1.73 (0.71-4.26)
Strong Weak 44 23 1.05 (0.46-2.40)
Strong 178 57 1.43 (0.64-3.20)
Low-grade serous Weak Weak 17 10 Reference .02
Strong 14 8 0.87 (0.28-2.71)
Strong Weak 24 11 0.78 (0.28-2.21)
Strong 84 45 0.33 (0.13-0.85)
aHR ¼ hazard ratio; MyD88 ¼ myeloid differentiation primary response gene 88; TLR4 ¼ Toll-like receptor 4.
bAdjusted for study, age (continuous), and stage (I/II, III/IV, unknown). P values from unordered 3 degree-of-freedom test.
MYD88 AND TLR4 IN EPITHELIAL OVARIAN CANCER(Supplemental Tables 8 and 9, available online
at http://www.mayoclinicproceedings.org).
Note that the number of tests conducted is
not small, no correction for multiple testing
was done, and sample sizes are quite reduced
in subset analyses.
DISCUSSION
Toll-like receptors, including TLR4, were orig-
inally described as myeloid leukocyte receptors
for pathogen-associated molecular patterns,
conserved structures present on subsets of
pathogens but absent on normal host cells.20
More recently, multiple endogenously
expressed molecules (damage-associated mo-
lecular patterns) have been shown to stimulate
myeloid cells via a TLR-dependent mecha-
nism.21 Speciﬁcally, TLR4 has been demon-
strated to be stimulated by hsp60, hsp70,
hsp90B1, heparan sulfate, ﬁbrinogen,
HMGB1, BD-2, and additional endogenous
molecules.21 Many of these damage-associated
molecular patterns are present in the EOC
microenvironment13 and could therefore drive
intracellular signaling through MyD88 and
TLR4 in EOC cells expressing these proteins.
The ligation of TLR4 triggers recruitment ofMayo Clin Proc. n March 2018;93(3):307-320 n https://doi.org/10.1
www.mayoclinicproceedings.orgthe adapter protein MyD88 to the receptor
complex. Upon recruitment, MyD88, in turn,
recruits the kinases IL-1 receptor-associated ki-
nase 1 and receptor-associated kinase 4. Once
active, receptor-associated kinase 1 and
receptor-associated kinase 4 recruit TNF recep-
toreassociated factor 6, which activates IkB ki-
nase. The activation of IkB kinase causes
degradation of inhibitor of kappa B, promoting
nuclear translocation and signaling by nuclear
factor kappa B.22 The signaling of nuclear factor
kappa B generates proliferative and antiapop-
totic signals in EOC cells.23,24
We and others have previously suggested
that MyD88 expression is associated with
poorer survival in EOC.13,25 This association
was conﬁrmed in the present study only for pa-
tients with HGSOC, albeit with a relatively
modest magnitude of effect after adjustment
for age at diagnosis, disease stage, and study
site. A likely explanation for the somewhat
attenuated effect in the covariate-adjusted anal-
ysis is that MyD88 also is associated with
advanced stage HGSOC. Thus, at least part of
the impact of MyD88 on survival may be
explained by its association with advanced
disease. In sharp contrast with HGSOC,016/j.mayocp.2017.10.023 315
TABLE 3. Associations of MyD88 and TLR4 Expression and Overall Survival Among HGSOC Cases by Extent of Residual Disease, by
Pathogenic Mutation Status, and by First-Line Chemotherapya,b
Clinical attribute Level
MyD88
Level
TLR4
N No. of events HR (95% CI) P N No. of events HR (95% CI) P
Extent of residual disease
Macroscopic disease Weak 274 202 Reference .45 Weak 292 219 Reference .08
Strong 800 659 1.07 (0.90-1.27) Strong 687 576 1.17 (0.98-1.39)
No macroscopic disease Weak 185 92 Reference .39 Weak 207 115 Reference .03
Strong 561 278 1.12 (0.87-1.44) Strong 476 238 0.76 (0.59-0.97)
Pathogenic mutation status
Tested negative Weak 152 90 Reference .02 Weak 147 99 Reference .16
Strong 485 347 1.33 (1.04-1.70) Strong 444 321 1.19 (0.94-1.51)
Pathogenic BRCA1 mutation Weak 23 11 Reference .70 Weak 27 10 Reference .01
Strong 82 50 1.18 (0.51-2.72) Strong 71 43 2.69 (1.25-5.81)
Pathogenic BRCA2 mutation Weak 13 4 Reference .69 Weak 11 6 Reference .02
Strong 35 15 1.30 (0.36-4.71) Strong 31 12 0.26 (0.08-0.84)
First-line chemotherapy treatment
Standard treatment Weak 59 36 Reference .27 Weak 102 62 Reference .77
Strong 280 176 1.24 (0.85-1.82) Strong 231 150 0.96 (0.68-1.37)
aAUC ¼ area under the concentration-time curve; BRCA1 ¼ breast cancer susceptibility gene 1; BRCA2 ¼ breast cancer susceptibility gene 2; HGSOC ¼ high-grade serous
ovarian cancer; HR, hazard ratio; MyD88 ¼ myeloid differentiation primary response gene 88; TLR4 ¼ Toll-like receptor 4.
bAdjusted for study, age (continuous), and stage (I/II, III/IV, unknown); mutation status reﬂects results of germline testing; standard treatment includes patients receiving 4
cycles of intravenous carboplatin AUC 5 or 6 and paclitaxel 135 mg/m2 or 175 mg/m2 every 3 wk and patients receiving 4 cycles of intravenous carboplatin and paclitaxel
every 3 wk with dose presumed to be carboplatin AUC 5 or 6 and paclitaxel 135 mg/m2 or 175 mg/m2.
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316improved survival in LGSOC was associated
with higher MyD88 expression. Furthermore,
TLR4 expression also correlated positively
with survival in LGSOC. Although the mecha-
nism behind these divergent effects is not clear,
the dichotomy of MyD88 and TLR4 associa-
tions between HGSOC and LGSOC adds
further evidence that these 2 histotypes are bio-
logically distinct. Understudied LGSOCs need
additional investigation. Another of the under-
studied histotypes, MOC, showed a nonsigniﬁ-
cant association between TLR4 expression and
prognosis, although this result was more pro-
nounced before accounting for the effects of
study site; consideration of similarities with
gastrointestinal tumors may help to unravel its
biology.26
Although this study is the largest to
examine the adaptor protein MyD88 and the
pathogen-associated molecular pattern recep-
tor TLR4, several signiﬁcant limitations were
unavoidable. First, the level of agreement be-
tween the 2 scorers for 4-scale MyD88 expres-
sion was modest, leading to the ﬁnal analysis
being performed on dichotomized data. A likely
reason for the lower level of agreement with a 4-
variable categorization is that the overall stain-
ing intensity of MyD88 was relatively modest.Mayo Clin Proc. n March 201This change to a 2-variable categorization
improved interscorer agreement butmight limit
the sensitivity of the analysis to detect subtle ef-
fects of MyD88 on survival. However, because
this limitation would reduce sensitivity for
detecting association between MyD88 staining
intensity and survival, it would not be expected
to contribute to false-discovery rate.We suggest
that future studies consider other ways to mea-
sure MyD88 and TLR4 expression, perhaps by
calculating the actual percent of cells positively
stained.CONCLUSION
The current study supports an association
between increased MyD88 expression and
poor survival in HGSOC and demonstrates
that increased MyD88 expression is also asso-
ciated with advanced stage HGSOC. In addi-
tion, the study suggests that both MyD88
expression and TLR4 expression are associated
with favorable survival in LGSOC.ACKNOWLEDGMENTS
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